APA citiranje

Jabbour, E., Kantarjian, H. M., Jones, D., Reddy, N., O'Brien, S., Garcia-Manero, G., . . . Cortes, J. (2008). Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. American Society of Hematology.

Citação norma Chicago

Jabbour, Elias, Hagop M. Kantarjian, Dan Jones, Neeli Reddy, Susan O'Brien, Guillermo Garcia-Manero, Jan Burger, and Jorge Cortes. Characteristics and Outcome of Chronic Myeloid Leukemia Patients With F317L BCR-ABL Kinase Domain Mutation After Therapy With Tyrosine Kinase Inhibitors. American Society of Hematology, 2008.

MLA citiranje

Jabbour, Elias, et al. Characteristics and Outcome of Chronic Myeloid Leukemia Patients With F317L BCR-ABL Kinase Domain Mutation After Therapy With Tyrosine Kinase Inhibitors. American Society of Hematology, 2008.